Balanced Risk Profile and Slower Near-Term Margin Expansion Support Neutral Stance on Idexx Laboratories

UBS analyst Andrea Alfonso has maintained their neutral stance on IDXX stock, giving a Hold rating today.

Andrea Alfonso has given his Hold rating due to a combination of factors related to Idexx Laboratories’ near-term growth and profitability profile. While he acknowledges positives such as ongoing benefits from increased diagnostic usage among the maturing cohort of “pandemic puppies” and the company’s ability to sustain premium pricing despite weaker clinical visit trends, he sees Q4 results raising more uncertainties than clarity. Specifically, he notes that first-quarter 2026 growth looks subdued even with a favorable calendar effect, management’s outlook implies a slower pace of gross margin expansion than in 2025, and projected deceleration in inVue analyzer placements during the second year contrasts with the trajectory of earlier product launches. These elements, combined with a still-soft macro backdrop and challenging early-2026 optics, lead him to view the near-term margin expansion story as less compelling.

At the same time, Alfonso has modestly increased revenue and EPS forecasts for 2026–2028, reflecting the carryover from stronger-than-expected Q4 2025 performance, slightly better expectations for recurring diagnostic revenue growth, and updated foreign-exchange assumptions. Even with these upward revisions, his revenue growth estimates sit toward the low end of management’s guidance range, underscoring his cautious stance on how robust the company’s growth will be. He trims his price target to $730 from $750 and bases it on a valuation multiple that aligns with the market’s current expectations for Idexx, arguing there is little justification for further multiple expansion given the mix of macro uncertainty and pipeline opportunities. Overall, he concludes that upside and downside risks are broadly balanced at the current valuation, supporting a Neutral (Hold) rather than a Buy or Sell recommendation.

According to TipRanks, Alfonso is a 4-star analyst with an average return of 49.0% and a 100.00% success rate. Alfonso covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, Zoetis, and Elanco Animal Health.

In another report released today, TipRanks – Anthropic also reiterated a Hold rating on the stock with a $691.00 price target.